Even if drug prices are flat, there will still be affordability problems if out-of-pocket costs are not addressed, the outgoing BIO CEO said in an interview with the Pink Sheet. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
